Cagrilintide vs Lixisenatide

Cagrilintide is an experimental long-acting amylin drug still in development, with no approved uses yet. Lixisenatide, sold as Adlyxin or Soliqua, is an FDA-approved GLP-1 receptor agonist used to treat type 2 diabetes. While both are injectable medications, cagrilintide is not yet available, whereas lixisenatide is already on the market.

AI summary of the sources below.